Immunostimulation in the treatment of viral infection
Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, those within the respiratory tract, particularly the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The systems may be used to treat pathogens, such as bacteria and viruses, particularly coronaviruses.
1. A method for treating a patient having an infection by a pathogen comprising:
positioning at least one electrode near a target tissue within the patient; and
delivering non-thermal pulsed electric field energy through at least one of the at least one electrode to the target tissue area so as to cause the infection to reduce, wherein the infection is reduced due to triggering of an immunostimulatory cascade within the patient that responds to the infection.
2. A method as in claim 1 , wherein the infection is additionally reduced due to direct destruction of the pathogen or due to triggering of a process that leads to programmed destruction of the pathogen.
3. A method as in claim 1 , wherein the infection is additionally reduced due to killing of cells infected with the pathogen or due to triggering of a process that leads to programmed death of the cells infected with the pathogen.
4. A method as in claim 1 , wherein the immunostimulatory cascade stimulates antibody production.
5. A method as in claim 1 , wherein the immunostimulatory cascade stimulates T-cell activation.
6. A method as in claim 1 , wherein the pathogen comprises a bacteria.
7. A method as in claim 6 , wherein the bacteria comprises Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia , opportunistic gram-negatives, Mycoplasma pneumoniae , and/or Chlamydia pneumoniae.
8. A method as in claim 1 , wherein the pathogen comprises a fungus.
9. A method as in claim 1 , wherein the pathogen comprises a virus.
10. A method as in claim 9 , wherein the virus comprises a rhinovirus, an influenzae or parainfluenza virus, a respiratory syncytial virus, a coronavirus, a herpes simplex virus, and/or an adenovirus.
11. A method as in claim 10 , wherein the virus comprises the coronavirus and the coronavirus comprises a SARS-CoV-2 virus.
12. A method as in claim 10 , wherein the virus comprises the coronavirus and the coronavirus comprises a Middle East Respiratory Syndrome Coronavirus (MERS-CoV) or a Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV).
13. A method as in claim 1 , wherein the target tissue is located within a bronchial tree of the patient.
14. A method as in claim 1 , wherein the target tissue is located along a respiratory tract, a nasal passageway, one or more turbinates, a nasal cavity, a pharynx, an oropharynx, one or more tonsils and/or an esophagus of the patient.
15. A method as in claim 1 , wherein the target tissue is located at or near a site of the infection.
16. A method as in claim 1 , wherein the energy is delivered prior to the development of symptoms of the infection.
17. A method as in claim 1 , wherein the energy is delivered at a time after symptoms of the infection have developed.
18. A method as in claim 1 , wherein the energy is provided by a waveform comprising at least one energy packet, wherein each energy packet comprises a series of biphasic pulses.
19. A method as in claim 18 , wherein the at least one energy packet has a frequency in the range of approximately 500-800 kHz.
20. A method as in claim 1 , wherein the at least one electrode comprises at least one protrusion expandable to contact the target tissue.
21. A method as in claim 20 , wherein the at least one protrusion comprises a plurality of wires forming an expandable basket, wherein at least one of the wires acts as the at least one electrode.
22. A method as in claim 1 , wherein the target tissue is disposed along a body passageway.
23. A method as in claim 22 , wherein the body passageway includes a blood vessel, a lymphatic vessel, a bile duct, a kidney tubule, an esophagus, a stomach, a small intestine, a large intestine, an appendix, a rectum, a bladder, a ureter, a pharynx, a mouth, a vagina, a urethra, or a duct of a gland.
24. A method for treating a patient having a viral infection comprising:
positioning an electrode within a portion of a respiratory tract of the patient near the viral infection; and
delivering a pulsed electric field energy to the electrode so that the energy is delivered to the portion of the respiratory tract in a manner that triggers an immunostimulatory cascade by the patient to reduce the viral infection.
25. A method as in claim 24 , wherein the immunostimulatory cascade stimulates antibody production.
26. A method as in claim 24 , wherein the immunostimulatory cascade stimulates T-cell activation.
27. A method for treating a patient having an infection by a pathogen comprising:
positioning at least one electrode near a target tissue within the patient; and
delivering non-thermal pulsed electric field energy through at least one of the at least one electrode to the target tissue area so as to cause the infection to reduce, wherein the pathogen comprises a bacteria.
28. A method as in claim 27 , wherein the target tissue is located within a bronchial tree of the patient or wherein the target tissue is located along a respiratory tract, a nasal passageway, one or more turbinates, a nasal cavity, a pharynx, an oropharynx, one or more tonsils and/or an esophagus of the patient.
29. A method as in claim 27 , wherein the bacteria comprises Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia , opportunistic gram-negatives, Mycoplasma pneumoniae , and/or Chlamydia pneumoniae.
30. A method as in claim 27 , wherein the target tissue is disposed along a body passageway.
31. A method as in claim 30 , wherein the body passageway includes a blood vessel, a lymphatic vessel, a bile duct, a kidney tubule, an esophagus, a stomach, a small intestine, a large intestine, an appendix, a rectum, a bladder, a ureter, a pharynx, a mouth, a vagina, a urethra, or a duct of a gland.
32. A method as in claim 27 , wherein the infection is reduced due to direct destruction of the pathogen or due to triggering of a process that leads to programmed destruction of the pathogen.
33. A method as in claim 27 , wherein the infection is reduced due to killing of cells infected with the pathogen or due to triggering of a process that leads to programmed death of the cells infected with the pathogen.
34. A method as in claim 27 , wherein the energy is provided by a waveform comprising at least one energy packet, wherein each energy packet comprises a series of biphasic pulses.
35. A method for treating a patient having an infection by a pathogen comprising:
positioning at least one electrode near a target tissue within the patient; and
delivering non-thermal pulsed electric field energy through at least one of the at least one electrode to the target tissue area so as to cause the infection to reduce, wherein the pathogen comprises a virus.
36. A method as in claim 35 , wherein the virus comprises a rhinovirus, an influenzae or parainfluenza virus, a respiratory syncytial virus, a coronavirus, a herpes simplex virus and/or an adenovirus.
37. A method as in claim 36 , wherein the virus comprises the coronavirus and the coronavirus comprises a SARS-CoV-2 virus.
38. A method as in claim 36 , wherein the virus comprises the coronavirus and the coronavirus comprises a Middle East Respiratory Syndrome Coronavirus (MERS-CoV) or a Severe Acute Respiratory Syndrome-associated coronavirus (SARS-CoV).
39. A method as in claim 35 , wherein the target tissue is located within a bronchial tree of the patient or along a respiratory tract, a nasal passageway, one or more turbinates, a nasal cavity, a pharynx, an oropharynx, one or more tonsils and/or an esophagus of the patient.
40. A method as in claim 35 , wherein the target tissue is disposed along a body passageway.
41. A method as in claim 40 , wherein the body passageway includes a blood vessel, a lymphatic vessel, a bile duct, a kidney tubule, an esophagus, a stomach, a small intestine, a large intestine, an appendix, a rectum, a bladder, a ureter, a pharynx, a mouth, a vagina, a urethra, or a duct of a gland.
42. A method as in claim 35 , wherein the infection is reduced due to direct destruction of the pathogen or due to triggering of a process that leads to programmed destruction of the pathogen.
43. A method as in claim 35 , wherein the infection is reduced due to killing of cells infected with the pathogen or due to triggering of a process that leads to programmed death of the cells infected with the pathogen.
44. A method as in claim 35 , wherein the target tissue is located at or near a site of the infection.
45. A method as in claim 35 , wherein the energy is provided by a waveform comprising at least one energy packet, wherein each energy packet comprises a series of biphasic pulses.
46. A method for treating a patient having an infection by a pathogen comprising:
positioning at least one electrode near a target tissue within the patient; and
delivering non-thermal pulsed electric field energy through at least one of the at least one electrode to the target tissue area so as to cause the infection to reduce, wherein the pathogen comprises a fungus.
47. A method as in claim 46 , wherein the energy is provided by a waveform comprising at least one energy packet, wherein each energy packet comprises a series of biphasic pulses.
48. A method for treating a patient having an infection by a pathogen comprising:
positioning at least one electrode near a target tissue within the patient; and
delivering non-thermal pulsed electric field energy through at least one of the at least one electrode to the target tissue area so as to cause the infection to reduce, wherein the energy is delivered prior to the development of symptoms of the infection.
49. A method for treating a patient having an infection by a pathogen comprising:
positioning at least one electrode near a target tissue within the patient; and
delivering non-thermal pulsed electric field energy through at least one of the at least one electrode to the target tissue area so as to cause the infection to reduce, wherein the energy is delivered at a time after symptoms of the infection have developed.
50. A method as in claim 49 , wherein the infection is reduced due to direct destruction of the pathogen or due to triggering of a process that leads to programmed destruction of the pathogen.
51. A method as in claim 49 , wherein the infection is reduced due to killing of cells infected with the pathogen or due to triggering of a process that leads to programmed death of the cells infected with the pathogen.
52. A method as in claim 49 , wherein the energy is provided by a waveform comprising at least one energy packet, wherein each energy packet comprises a series of biphasic pulses.